Health sciences

Anixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological Assays

Monday, June 1, 2020 - 1:30pm

Anixa and OntoChem announced their partnership on April 20, 2020 ( https://ir.anixa.com/press-releases/detail/947/ ) and announced discovery of its first potential Covid-19 candidate two weeks later on May 4, 2020.

Key Points: 
  • Anixa and OntoChem announced their partnership on April 20, 2020 ( https://ir.anixa.com/press-releases/detail/947/ ) and announced discovery of its first potential Covid-19 candidate two weeks later on May 4, 2020.
  • As the computer-based screening identified potential compounds, they would be synthesized and tested in biological assays to evaluate their potency as predicted by the molecular modeling algorithms.
  • Should the biological activity be verified, the compounds will be tested in animal studies to further evaluate their candidacy as Covid-19 therapeutics.
  • These compounds have been synthesized and we are now engaged in testing these compounds in biological assays to verify the efficacy that was predicted in silico."

Zen Leaf Enters New Jersey Medical Market with New Dispensary in Elizabeth

Monday, June 1, 2020 - 2:00pm

The established cannabis retailer, which already operates dispensaries across six states & Puerto Rico, welcomes the New Jersey medical cannabis community to its new storefront at 117 Spring Street in Elizabeth.

Key Points: 
  • The established cannabis retailer, which already operates dispensaries across six states & Puerto Rico, welcomes the New Jersey medical cannabis community to its new storefront at 117 Spring Street in Elizabeth.
  • In accordance with guidelines set forth by health authorities, Zen Leaf is operating with capacity limits until further notice.
  • Zen Leaf is a dispensary brand dedicated to enriching its patients quality of life by providing safe access to lab-tested, premium medical cannabis products.
  • Zen Leaf puts forth an extensive menu of medical cannabis products, including flower, concentrates, edibles, tablets and topicals, in precision-dosed THC and CBD formulations, from the most coveted cultivators/processors in New Jersey.

Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection

Monday, June 1, 2020 - 1:00pm

Proteona today announced that Twist Bioscience Corporation (Nasdaq: TWST) will join the international alliance led by Proteona to develop neutralizing antibody therapy against COVID-19 for vulnerable immunocompromised patients.

Key Points: 
  • Proteona today announced that Twist Bioscience Corporation (Nasdaq: TWST) will join the international alliance led by Proteona to develop neutralizing antibody therapy against COVID-19 for vulnerable immunocompromised patients.
  • The international alliance was initiated by Proteona in response to the urgent need of patients most at risk facing the pandemic, such as those with blood cancers.
  • The alliance aims to develop antibody therapies to provide a safe and targeted treatment for these vulnerable populations.
  • Twist Bioscience is an instrumental addition to the alliance, said Andreas Schmidt, CEO of Proteona.

WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit

Monday, June 1, 2020 - 1:00pm

Dr. Chang brings strong leadership and a wealth of experience in cell and gene therapy and biopharmaceutical technical development, manufacturing operations, engineering and strategy.

Key Points: 
  • Dr. Chang brings strong leadership and a wealth of experience in cell and gene therapy and biopharmaceutical technical development, manufacturing operations, engineering and strategy.
  • "We are delighted to welcome Dr. Chang as CEO of WuXi ATU to lead our cell and gene therapy CDMO business to the next stage of growth," said Mr. Edward Hu, Vice Chairman and Global Chief Investment Officer of WuXi AppTec.
  • "I'm very honored to join WuXi AppTec," said Dr. Chang.
  • As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

TheraPsil launches program to assist patients in accessing legal, psilocybin-assisted psychotherapy

Monday, June 1, 2020 - 1:00pm

TheraPsil, a BC-based non-profit coalition of Healthcare professionals, patients, and advocates, will help qualified patients file for an exemption directly to the federal Minister of Health, who has the authority to allow the treatment.

Key Points: 
  • TheraPsil, a BC-based non-profit coalition of Healthcare professionals, patients, and advocates, will help qualified patients file for an exemption directly to the federal Minister of Health, who has the authority to allow the treatment.
  • Canadians with a terminal diagnosis, experiencing psychological end-of-life distress, deserve the right to try new therapies that can improve their quality of life and death.
  • When a safe and effective therapy involves a prohibited substance, we help patients exercise their rights - to align with science and support those in need.
  • Interested Health care professionals, and individuals experiencing end-of-life distress are invited to confidentially contact us on the TheraPsil website.

Delta 9 Completes Transaction to Acquire Two Alberta Retail Stores

Monday, June 1, 2020 - 1:00pm

WINNIPEG, Manitoba, June 01, 2020 (GLOBE NEWSWIRE) -- DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (Delta 9 or the Company), is pleased to announce that on May 29, 2020 it closed a transaction with Modern Leaf Group Inc. ("Modern Leaf") to acquire all or substantially all of Modern Leafs assets located in the Province of Alberta relating to two retail cannabis stores located in Calgary, Alberta and Grande Prairie, Alberta (the "Transaction").

Key Points: 
  • WINNIPEG, Manitoba, June 01, 2020 (GLOBE NEWSWIRE) -- DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (Delta 9 or the Company), is pleased to announce that on May 29, 2020 it closed a transaction with Modern Leaf Group Inc. ("Modern Leaf") to acquire all or substantially all of Modern Leafs assets located in the Province of Alberta relating to two retail cannabis stores located in Calgary, Alberta and Grande Prairie, Alberta (the "Transaction").
  • "We are pleased to have finalized our transaction with Modern Leaf and look forward to the first Delta 9 Cannabis Stores opening their doors in the province of Alberta in short order," said John Arbuthnot, CEO of Delta 9.
  • The purchase price paid by Delta 9 Cannabis Store Inc. relating to the Transaction was $1,300,000, subject to customary adjustments (the "Purchase Price").
  • Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand.

Genekam Plasma Therapy Accelerator: a New solution for Better Antibody Therapy for All Coronavirus Patients

Friday, May 29, 2020 - 2:30pm

This will solve the shortage problem also of therapy as millions of persons recovered from coronavirus 2020 can donate the plasma many times a year.

Key Points: 
  • This will solve the shortage problem also of therapy as millions of persons recovered from coronavirus 2020 can donate the plasma many times a year.
  • SARS-Hunter is a quickest solution for creation of effective antibodies therapy with low costs for all patients around the world.
  • View the full release here: https://www.businesswire.com/news/home/20200529005307/en/
    Plasma Therapy Accelerator: a New Solution for Better Antibody Therapy for All Coronavirus Patients (Photo: Business Wire)
    Plasma from coronavirus recovered patients is being used as one of the successful therapeutic options to treat the corona virus-infected patients because it is rich in corona virus-specific antibodies.
  • SARS-hunter can have a very strong impact on the antibody therapy and should make available antibody therapy to a large population.

Global Capsule Filler Market to Expand as New Manufacturing Technologies Gain Popularity Across the Pharmaceutical Industry- TMR

Friday, May 29, 2020 - 1:00pm

The growing use of manufacturing technologies in the pharmaceutical industry has created a stir across this market.

Key Points: 
  • The growing use of manufacturing technologies in the pharmaceutical industry has created a stir across this market.
  • The pharmaceutical industry has lately embraced the use of nascent systems, machines, and technologies that can ease manufacturing operations.
  • In light of these factors, the global capsule filler market is set to create a huge opportunity for the leading vendors.
  • In this review, several factors pertaining to market growth and expansion for the global capsule filler market have been enunciated.

Global Capsule Filler Market to Expand as New Manufacturing Technologies Gain Popularity Across the Pharmaceutical Industry- TMR

Friday, May 29, 2020 - 1:00pm

The growing use of manufacturing technologies in the pharmaceutical industry has created a stir across this market.

Key Points: 
  • The growing use of manufacturing technologies in the pharmaceutical industry has created a stir across this market.
  • The pharmaceutical industry has lately embraced the use of nascent systems, machines, and technologies that can ease manufacturing operations.
  • In light of these factors, the global capsule filler market is set to create a huge opportunity for the leading vendors.
  • In this review, several factors pertaining to market growth and expansion for the global capsule filler market have been enunciated.

Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

Friday, May 29, 2020 - 1:00pm

XENLETA has a novel mechanism of action and provides an urgently needed short course, empiric monotherapy treatment alternative for adult patients with CAP.

Key Points: 
  • XENLETA has a novel mechanism of action and provides an urgently needed short course, empiric monotherapy treatment alternative for adult patients with CAP.
  • The U.S. Food and Drug Administration (FDA) approved XENLETA in August 2019 for the treatment of adult patients with community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team.